摘要
目的观察帕罗西汀对致残精神分裂症患者阴性症状的改善程度。方法对100例长期住院的致残精神分裂症患者在常规抗精神疾病药物治疗基础上加用帕罗西汀，在治疗前及治疗3、6、12个月时采用阴性症状量表（SANS）、残疾水平评定量表（WHODASⅡ）、药物副反应量表（TESS）对患者阴性症状、残疾水平及用药安全性进行评定。结果与治疗前比较，患者使用帕罗西汀3个月时SANS中兴趣缺乏因子、注意障碍因子改善[分别为（17．4±4．8）分比（18．9±3．6）分，（11．0±3．6）分比（12．5±4．8）分]（均P〈0．05）；6个月时意志缺乏、思维贫乏、情感平淡3项因子均有改善[分别为（12．1±3．7）分比（13．4±3．6）分，（12．8±3．6）分比（13．8±2．1）分，（9．5±2．5）分比（10．4±3．8）分]（均P〈0．05）；12个月时兴趣缺乏、注意障碍、意志缺乏、思维贫乏、情感平淡5项因子均明显改善[SANS评分分别为（11．7±2．1）、（7．4±2．6）、（9．7±2．6）、（8．0±2．4）、（7．0±2．1）分]（均P〈0．01）。6个月时WHODASⅡ评分为（32±13）分，12个月时WHODASⅡ评分为（29±10）分，与治疗前WHODASⅡ评分[（37±14）分]比较，差异均有统计学意义（P〈0．01）。治疗6个月时TESS评分为（14．5±3．8）分，12个月时为（9．6±2．3）分，与治疗前TESS评分[（15．8±3．6）分]比较，差异均有统计学意义（P〈0．05和P〈0．01）。结论致残精神分裂症患者使用帕罗西汀后阴性症状得到明显改善，残疾水平下降，疗效确切，安全性高。
Objective To observe the improvement of negative symptoms in disabled schizophrenic patients using paroxetine. Methods All 100 disabled schizophrenic patients who needed for prolonged hospitalization were cured by paroxetine on the basis of conventional antipsychotic medication. The degree of disability, negative symp- toms and safety by scale for the assessment of negative symptoms（ SANS）, WHO disability assessment schedule ver- sion 2 （WHODAS II ） and treatment emergent symptom scale （TESS） before treatment and three months, half a year, one year after treatment were observed. Results Compared with before treatment, the factors of interest-lack and attention-disorder started to show improvement after three months of treatment[ （ 17.4±4.8） points vs（ 18.9±3.6） points, （ 11.0±3.6） points vs （ 12.5±4.8 ） points, respectively, all P 〈 0.05 ], and the factors of will-lack, emotional apathy, thought-poverty started to show improvement after half a year of treatment[ （ 12.1±3.7 ）points vs （ 13.4±5.6） points, （ 12.8±5.6） points vs （ 13.8±2.1 ） points, （9.5±2.5 ） points vs （ 10.4±5.8） points, re- spectively]. The scores of interest-lack, attention-disorder, will-lack, emotional apathy and thought-poverty after one year of treatment were （ 11.7±2.1 ） points, （7.4±2. 6） points, （9.7±2. 6） points, （8.0±2.4） points, （7.0±2.1 ） points, respectively, which all showed significant improvement（ all P 〈 0. O1 ）. The scores of WHODAS II for half a year and one year of treatment were lower than that before treatment [ （32±13 ）points vs （37±14）points and （29±10） points vs （37±14） points, P 〈 0.05 and P 〈 0.01 ]. Compare with before treatment, the scores of TESS started to reduce after half a year of treatment [ （ 14.5±3.8） points vs （ 15.8±3.6） points, P 〈 0.05 ], and significantly reduced after one year of treatment [ （9.6±2.3 ）points vs （ 15.8±3.6） points,P 〈0.01 ]. Conclusions Negative sym
出处
《中国医药》
2012年第7期850-851,共2页
China Medicine
关键词
残疾
帕罗西汀
精神分裂症
阴性症状
Disability
Paroxetine
Schizophrenia
Negative symptoms
